The GRAPPA-OMERACT Working Group: 4 Prioritized Domains for Completing the Core Outcome Measurement Set for Psoriatic Arthritis 2019 Updates

Ying Ying Leung^{1

2}, William Tillett^{3

4}, Ana-Maria Orbai^{3

4}, Alexis Ogdie^{3

4}, Lihi Eder^{3

4}, Laura C Coates^{3

4}, Richard Holland^{3

4}, Anna Antony^{3

4}, Niti Goel^{3

4}, Philip J Mease^{3

4}, Vibeke Strand^{3

4}, Oliver FitzGerald^{3

4}, Maarten de Wit^{3

4}, Christine A Lindsay^{3

4}, Kristina Callis Duffin^{3

4}, Dafna D Gladman^{3

4}

Affiliations

¹ From Duke-National University of Singapore (NUS) Medical School, Singapore, Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Women's College Research Institute, Women's College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Concord Repatriation General Hospital, Sydney, Australia; Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; Caduceus Biomedical Consulting LLC, Raleigh; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Double X Management Inc., Prosper, Texas; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; University of Toronto, Krembil Research Institute, and Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. katyccc@hotmail.com.
² Y.Y. Leung is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. A.M. Orbai is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the US National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the US National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). A. Ogdie is funded by the RRF and NIH/NIAMS K23 AR063764 and R01 AR072363. L.C. Coates is funded by an NIH Research (NIHR) Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the UK Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, Department of Medicine, University of Toronto; L.C. Coates, MB ChB, PhD, NIHR Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; R. Holland, MBBS, Concord Repatriation General Hospital; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting LLC, and Adjunct Assistant Professor, Duke University School of Medicine; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin; M. de Wit, PhD, Patient Research Partner, Amsterdam, the Netherlands; C.A. Lindsay, PharmD, Patient Research Partner, President, Double X Management Inc.; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital. katyccc@hotmail.com.
³ From Duke-National University of Singapore (NUS) Medical School, Singapore, Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Women's College Research Institute, Women's College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Concord Repatriation General Hospital, Sydney, Australia; Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; Caduceus Biomedical Consulting LLC, Raleigh; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Double X Management Inc., Prosper, Texas; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; University of Toronto, Krembil Research Institute, and Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada.
⁴ Y.Y. Leung is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. A.M. Orbai is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the US National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the US National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). A. Ogdie is funded by the RRF and NIH/NIAMS K23 AR063764 and R01 AR072363. L.C. Coates is funded by an NIH Research (NIHR) Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the UK Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, Department of Medicine, University of Toronto; L.C. Coates, MB ChB, PhD, NIHR Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; R. Holland, MBBS, Concord Repatriation General Hospital; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting LLC, and Adjunct Assistant Professor, Duke University School of Medicine; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin; M. de Wit, PhD, Patient Research Partner, Amsterdam, the Netherlands; C.A. Lindsay, PharmD, Patient Research Partner, President, Double X Management Inc.; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital.

PMID: 32482768
DOI: 10.3899/jrheum.200127

The GRAPPA-OMERACT Working Group: 4 Prioritized Domains for Completing the Core Outcome Measurement Set for Psoriatic Arthritis 2019 Updates

Ying Ying Leung et al. J Rheumatol Suppl. 2020 Jun.

. 2020 Jun:96:46-49.

doi: 10.3899/jrheum.200127.

Authors

Affiliations

¹ From Duke-National University of Singapore (NUS) Medical School, Singapore, Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Women's College Research Institute, Women's College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Concord Repatriation General Hospital, Sydney, Australia; Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; Caduceus Biomedical Consulting LLC, Raleigh; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Double X Management Inc., Prosper, Texas; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; University of Toronto, Krembil Research Institute, and Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. katyccc@hotmail.com.
² Y.Y. Leung is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. A.M. Orbai is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the US National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the US National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). A. Ogdie is funded by the RRF and NIH/NIAMS K23 AR063764 and R01 AR072363. L.C. Coates is funded by an NIH Research (NIHR) Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the UK Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, Department of Medicine, University of Toronto; L.C. Coates, MB ChB, PhD, NIHR Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; R. Holland, MBBS, Concord Repatriation General Hospital; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting LLC, and Adjunct Assistant Professor, Duke University School of Medicine; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin; M. de Wit, PhD, Patient Research Partner, Amsterdam, the Netherlands; C.A. Lindsay, PharmD, Patient Research Partner, President, Double X Management Inc.; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital. katyccc@hotmail.com.
³ From Duke-National University of Singapore (NUS) Medical School, Singapore, Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Women's College Research Institute, Women's College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Concord Repatriation General Hospital, Sydney, Australia; Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; Caduceus Biomedical Consulting LLC, Raleigh; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Double X Management Inc., Prosper, Texas; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; University of Toronto, Krembil Research Institute, and Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada.
⁴ Y.Y. Leung is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. A.M. Orbai is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the US National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the US National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). A. Ogdie is funded by the RRF and NIH/NIAMS K23 AR063764 and R01 AR072363. L.C. Coates is funded by an NIH Research (NIHR) Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the UK Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, Department of Medicine, University of Toronto; L.C. Coates, MB ChB, PhD, NIHR Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; R. Holland, MBBS, Concord Repatriation General Hospital; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting LLC, and Adjunct Assistant Professor, Duke University School of Medicine; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin; M. de Wit, PhD, Patient Research Partner, Amsterdam, the Netherlands; C.A. Lindsay, PharmD, Patient Research Partner, President, Double X Management Inc.; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital.

PMID: 32482768
DOI: 10.3899/jrheum.200127

Abstract

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) working group provided updates at the 2019 GRAPPA annual meeting on its work toward developing a core outcome set for PsA. The working group prioritized 4 domains, including musculoskeletal disease activity (enthesitis and dactylitis), fatigue, physical function, and structural damage. In this report, the working group summarizes its progress in standardizing the core outcome set for these 4 domains.

Keywords: GRAPPA; OMERACT; OUTCOME MEASURES; PSORIASIS; PSORIATIC ARTHRITIS.

PubMed Disclaimer

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The GRAPPA-OMERACT Working Group: 4 Prioritized Domains for Completing the Core Outcome Measurement Set for Psoriatic Arthritis 2019 Updates

Affiliations

The GRAPPA-OMERACT Working Group: 4 Prioritized Domains for Completing the Core Outcome Measurement Set for Psoriatic Arthritis 2019 Updates

Authors

Affiliations

Abstract

Publication types

MeSH terms

LinkOut - more resources

Medical

Research Materials

Miscellaneous